Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic re...
Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis
About this item
Full title
Author / Creator
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
The mortality effects and risk–benefit profile of low dose rivaroxaban (2.5 mg twice daily) in patients with coronary heart disease are not completely understood. Five randomized controlled trials (26,110 patients) were selected using PubMed and Cochrane library till April 2019. The background antiplatelet therapy was aspirin in 3 trials, P2Y12 inh...
Alternative Titles
Full title
Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7554154
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7554154
Other Identifiers
ISSN
0929-5305
E-ISSN
1573-742X
DOI
10.1007/s11239-020-02114-7
